Biomarin's current challenges include threats to key drugs and patent expiry issues, which could impact its medium-term performance. However, the potential for a sale and a promising long-term revenue outlook with new management targeting $4bn by 2027 and mid-teen growth could positively influence investor sentiment in the short term.